This article is more than 5 years old. Information may no longer be current.

Nicox reports revenue increase in first quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Nicox reported €2.1 million of revenue in the first quarter 2015 compared with €0.9 million in the first quarter of the previous year, according to a press release.

Cash, cash equivalents and financial instruments totaled €48.4 million as of March 31.

Gross proceeds from financing that closed in March totaled approximately €27 million.

Nicox held two pre-new drug application meetings with the FDA in the first quarter for AC-170 cetirizine ophthalmic solution for the treatment of ocular itching from allergic conjunctivitis. The company is aiming to have the treatment approved by the end of 2016.